Brought to you by 
King buys Elan's primary care pharma unit
09 Dec 2020
Executive Summary
In support of its efforts to divest its non-core businesses, Elan Corp. sold to King Pharmaceuticals (acquires and sells branded pharmaceuticals) its US primary care pharmaceuticals unit for €786mm ($850mm) in cash.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
King buys Elan's primary care pharma unit
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice